Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy

Nannan Wang, Ru Bu, Zhiyu Duan, Xueguang Zhang, Pu Chen, Zuoxiang Li, Jie Wu, Guangyan Cai, Xiangmei Chen

Background: MicroRNAs (miRNAs) have been found in virtually all body fluids and used successfully as biomarkers for various diseases. Evidence indicates that miRNAs have important roles in IgA nephropathy (IgAN), a major cause of renal failure. In this study, we looked for differentially expressed miRNAs in IgAN and further evaluated the correlations between candidate miRNAs and the severity of IgAN.

Methods: Microarray and RT-qPCR (real-time quantitative polymerase chain reaction) were sequentially used to screen and further verify miRNA expression profiles in urinary sediments of IgAN patients in two independent cohorts. The screening cohort consisted of 32 urine samples from 18 patients with IgAN, 4 patients with MN (membranous nephropathy), 4 patients with MCD (minimal changes disease) and 6 healthy subjects; the validation cohort consisted of 102 IgAN patients, 41 MN patients, 27 MCD patients and 34 healthy subjects. The renal pathological lesions of patients with IgAN were evaluated according to Lee’s grading system and Oxford classification.

Results: At the screening phase, significance analysis of microarrays analysis showed that no miRNA was differentially expressed in the IgAN group compared to all control groups. But IgAN grade I-II and III subgroups (according to Lee’s grading system) shared dysregulation of two miRNAs (miR-3613-3p and miR-4668-5p). At the validation phase, RT-qPCR results showed that urinary level of miR-3613-3p was significantly lower in IgAN than that in MN, MCD and healthy controls (0.47, 0.44 and 0.24 folds, respectively, all \( P < 0.01 \) by Mann-Whitney U test); urinary level of miR-4668-5p was also significantly lower in IgAN than that in healthy controls(0.49 fold, \( P < 0.01 \)). Significant correlations were found between urinary levels of miR-3613-3p with 24-hour urinary protein excretion (Spearman \( r = 0.50, P = 0.034 \)), eGFR (estimated glomerular filtration rate) (\( r = -0.48, P = 0.043 \)) and Lee’s grades (\( r = 0.57, P = 0.014 \)). Similarly, miR-4668-5p was significantly correlated with eGFR (r = -0.50, \( P = 0.034 \)) and Lee’s grades (r = 0.57, \( P = 0.013 \)). For segmental glomerulosclerosis according to Oxford classification, patients scored as S0 had significantly lower levels of urinary miR-3613-3p and miR-4668-5p than those scored as S1.
(0.41 and 0.43 folds, respectively, all $P < 0.05$).

Conclusions: The expression profile of miRNAs was significantly altered in urinary sediments from patients with IgAN. Urinary expression of miR-3613-3p was down-regulated in patients with IgAN. Moreover, urinary levels of both miR-3613-3p and miR-4668-5p were correlated with disease severity. Further studies are needed to explore the roles of miR-3613-3p and miR-4668-5p in the pathogenesis and progression of IgA nephropathy.
Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy

Nannan Wang, Ru Bu, Zhiyu Duan, Xueguang Zhang, Pu Chen, Zuoxiang Li, Jie Wu, Guangyan Cai, Xiangmei Chen

Background: MicroRNAs (miRNAs) have been found in virtually all body fluids and used successfully as biomarkers for various diseases. Evidence indicates that miRNAs have important roles in IgA nephropathy (IgAN), a major cause of renal failure. In this study, we looked for differentially expressed miRNAs in IgAN and further evaluated the correlations between candidate miRNAs and the severity of IgAN.

Methods: Microarray and RT-qPCR (real-time quantitative polymerase chain reaction) were sequentially used to screen and further verify miRNA expression profiles in urinary sediments of IgAN patients in two independent cohorts. The screening cohort consisted of 32 urine samples from 18 patients with IgAN, 4 patients with MN (membranous nephropathy), 4 patients with MCD (minimal changes disease) and 6 healthy subjects; the validation cohort consisted of 102 IgAN patients, 41 MN patients, 27 MCD patients and 34 healthy subjects. The renal pathological lesions of patients with IgAN were evaluated according to Lee’s grading system and Oxford classification.
Results: At the screening phase, significance analysis of microarrays analysis showed that no miRNA was differentially expressed in the IgAN group compared to all control groups. But IgAN grade I-II and III subgroups (according to Lee’s grading system) shared dysregulation of two miRNAs (miR-3613-3p and miR-4668-5p). At the validation phase, RT-qPCR results showed that urinary level of miR-3613-3p was significantly lower in IgAN than that in MN, MCD and healthy controls (0.47, 0.44 and 0.24 folds, respectively, all \( P < 0.01 \) by Mann-Whitney U test); urinary level of miR-4668-5p was also significantly lower in IgAN than that in healthy controls (0.49 fold, \( P < 0.01 \)). Significant correlations were found between urinary levels of miR-3613-3p with 24-hour urinary protein excretion (Spearman \( r = 0.50, P = 0.034 \)), eGFR (estimated glomerular filtration rate) (\( r = -0.48, P = 0.043 \)) and Lee’s grades (\( r = 0.57, P = 0.014 \)). Similarly, miR-4668-5p was significantly correlated with eGFR (\( r = -0.50, P = 0.034 \)) and Lee’s grades (\( r = 0.57, P = 0.013 \)). For segmental glomerulosclerosis according to Oxford classification, patients scored as S0 had significantly lower levels of urinary miR-3613-3p and miR-4668-5p than those scored as S1 (0.41 and 0.43 folds, respectively, all \( P < 0.05 \)).

Conclusions: The expression profile of miRNAs was significantly altered in urinary sediments from patients with IgAN. Urinary expression of miR-3613-3p was down-regulated in patients with IgAN. Moreover, urinary levels of both miR-3613-
3p and miR-4668-5p were correlated with disease severity. Further studies are needed to explore the roles of miR-3613-3p and miR-4668-5p in the pathogenesis and progression of IgA nephropathy.
Nannan Wang, Ru Bu, Zhiyu Duan, Xueguang Zhang, Pu Chen, Zuoxiang Li, Jie Wu, Guangyan Cai, Xiangmei Chen*

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China

Corresponding author: Xiangmei Chen

Address: Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, 28 Fuxing Road, Beijing 100853, China.

Tel: +86 010 66935462; fax: +86 010 68130297.

E-mail addresses: xmchen301@126.com
Introduction

Immunoglobulin A nephropathy (IgAN), the most common type of primary glomerulonephritis worldwide, is characterized by a predominant deposition of IgA-containing immune complexes in the glomerular mesangium (Wyatt & Julian 2013). The diagnosis of IgAN relies entirely on a renal biopsy, which is invasive and cannot be frequently repeated in the same patient. The prognosis of this disease is good in the early stages, but over the next 20 years, up to 40% of affected patients will develop irreversible end-stage renal disease (ESRD) (Schena 1990). Therefore, the development of non-invasive biomarkers would be of great significance for clinical assessment of IgAN.

In recent years, the role of microRNAs (miRNAs) in a variety of physiological and pathophysiological processes has received much attention. MiRNAs are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level (Esteller 2011). It has been demonstrated that miRNAs exhibit functional dysregulation in IgAN (Chandrasekaran et al. 2012; Szeto & Li 2014). As miRNAs are easily accessible, relatively stable and resistant to RNase-mediated degradation in body fluids (Chen et al. 2008), they have the potential to be used as non-invasive biomarkers.

Recent studies have shown that urinary levels of several selected miRNAs were significantly changed in patients with IgAN compared to healthy individuals (Wang et al. 2010; Wang et al. 2011). However, to date, no data are available concerning the global urinary profile of miRNAs in IgAN patients, and a study with both healthy controls and disease controls is lacking. Therefore, the aim of this study is to find differentially expressed miRNAs in urinary sediments from IgAN patients, and further evaluate the correlations between candidate miRNAs and the severity of IgAN.

Methods

Statement on ethics

The study was carried out in accordance with the Declaration of Helsinki for Human Research and
approved by the Ethics Committee of the Chinese PLA General Hospital (approval number S2014-004-02).

Written informed consent for inclusion was obtained from each participant.

**Study design**

A screening and a validation phase were designed for the present study. Besides healthy controls, we recruited patients with membranous nephropathy (MN) or minimal change disease (MCD) as other glomerulopathy controls. In the screening phase, 32 urine samples collected from 18 patients with IgAN and 14 controls were subjected to Affymetrix GeneChip miRNA 4.0 Array to identify miRNAs that were significantly differentially expressed. In the validation phase, the expression of different miRNAs was validated by real-time quantitative polymerase chain reaction (RT-qPCR) in samples from 102 patients with IgAN, 41 patients with MN, 27 patients with MCD and 34 healthy controls.

**Enrollment of subjects**

Patients who received renal biopsy for the first time from December 2013 to November 2014 at the Nephrology Department of the Chinese PLA General Hospital were consecutively recruited for the present study. The diagnosis was confirmed based on clinical findings and renal biopsies. A total of 322 consecutive patients were diagnosed as IgAN, MN or MCD. Among them, we excluded 41 patients because they were < 20 or > 50 years old at renal biopsy, 26 patients because they had been treated with steroids within 6 months prior to renal biopsy, and 7 patients because there were less than eight glomeruli in light microscopy sections. We also excluded patients with a concomitant diagnosis of chronic hepatic disease (n = 14), diabetes (n = 11), urinary, respiratory or gastrointestinal tract infection (n = 7), rheumatoid arthritis (n = 3), Henoch-Schonlein purpura (n = 7) and systemic lupus erythematosus (n = 10).

Healthy volunteers who were between 20 and 50 years old were recruited at the Physical Examination Center of the same hospital. All of them had normal renal function, normal urinalysis results, and no personal or family history of nephropathy or other serious illness.
Finally, 120 patients with IgAN, 45 patients with MN, 31 patients with MCD and 40 healthy volunteers were enrolled in this study. Among the IgAN patients, the first 6 patients with grade I-II according to Lee’s grading system who met the inclusion criteria and a sex ratio of 1 to 1 were selected as a screening cohort, as well as 6 patients with grade III and 6 patients with grade IV-V. In addition, 14 age- and gender-matched controls which included 4 patients with MN, 4 patients with MCD and 6 healthy volunteers were selected in the screening cohort.

The demographic and clinical data, such as age, gender, mean aortic pressure (MAP), serum creatinine (Scr) and 24-hour urinary protein excretion (UPE), of all included participants were recorded at the time of kidney biopsy. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD – EPI) equations (Levey et al. 2009).

**Evaluation of renal pathological lesion**

Renal tissues obtained by biopsy were stained with haematoxylin and eosin (H &E), periodic acid Schiff (PAS), periodic acid silver methenamine (PASM) and Masson's trichrome for light microscopy and with IgG, IgA, IgM, C3 and C1q for immunofluorescence. Two pathologists who were blinded to patients' data evaluated the renal biopsy slides separately.

For patients with IgAN, the severity of renal pathological lesions were evaluated according to Lee’s grading system (Lee et al. 1982) and Oxford classification (Roberts et al. 2009). First, all cases of IgAN were categorized into grade I-V according to Lee’s grading system. Then, four variables of Oxford classification were further evaluated; that is, mesangial proliferation (M1 - more than half the glomeruli have more than three cells in a mesangial area, M0 - not meet the criteria of M1), endocapillary hypercellularity (E1 - present, E0 - absent), segmental glomerulosclerosis (S1 - present, S0 – absent ), and tubular atrophy/ interstitial fibrosis (T0 - 0% – 25%, T1 - 26% – 50%, T2 - > 50%).

**Urine sample preparation**
A whole-stream early morning urine specimen was collected at the day of renal biopsy. The urine sample was centrifuged at 3,000 g for 30 min and at 13,000 g for 5 min at 4°C; supernatant was discarded (Wang et al. 2012; Wang & Szeto 2013). Then the urinary cell pellet was lysed by RNA lysis buffer MZ (Tiangen Biotech, Beijing, China, catalog number DP501) and stored at –80°C until used.

RNA extraction

Total RNA was extracted using a miRcute miRNA Isolation Kit (Tiangen Biotech, Beijing, China, catalog number DP501) according to the manufacturer's protocol. The quantity (ng/ml) and purity (ratio of absorbances of the RNA isolates at 260 nm and 280 nm [A260/280]) of the RNAs obtained was evaluated by NanoDrop 2000 spectrophotometer (Thermo Scientific, USA).

MiRNA microarray analysis

Affymetrix GeneChip miRNA 4.0 Array (Affymetrix, US, catalog number 902411), which covers all of the 2,578 mature human miRNAs available in miRBase version 20 (June 24, 2013, www.mirbase.org/) (Kozomara & Griffiths-Jones 2011), was used to profile miRNA expressions. Briefly, 1 µg of RNA was polyA tailed and labelled with a FlashTag Biotin HSR RNA Labeling Kit (Affymetrix, US, catalog number 901911). The labelled RNA was hybridized at 48°C for 16 hr on the miRNA arrays, which were washed and stained with Affymetrix Fluidics Station 450 (Affymetrix, US) and scanned with an Affymetrix GeneChip Scanner 3000 (Affymetrix, US) using the Command Console software (Affymetrix, US). The data were analyzed with miRNA QCTool (Affymetrix, US) using the Affymetrix default analysis settings and quantile as the normalization method. The microarray data have been deposited in Gene Expression Omnibus (GEO) at NCBI (http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE64306.

RT-qPCR analysis

RT-qPCR was carried out in compliance with the MIQE guidelines (Bustin et al. 2009) to verify the candidate miRNAs revealed by microarray. Briefly, reverse transcription was performed using 500 ng of total
RNA and a miRcute miRNA First-Strand cDNA Synthesis Kit (Tiangen Biotech, Beijing, China, catalog number KR201) according to the manufacturer’s protocol. RT-qPCR was performed on an Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Applied Biosystems, USA) using a miRcute miRNA qPCR Detection Kit (Tiangen Biotech, Beijing, China, catalog number FP401), according to the manufacturer’s instructions. All of the primers were purchased from Tiangen Biotech Company (Beijing, China). All PCR reactions were performed in triplicate, followed by melt curve analysis to verify their specificity and identity. U6 was selected as the endogenous reference control (Mestdagh et al. 2009). Relative miRNA expression levels were calculated using the \( \Delta \Delta Ct \) method as previously described (Livak & Schmittgen 2001).

### MiRNA target prediction and function analysis

The candidate miRNAs were imported into the miRWalk algorithm (Dweep et al. 2011) (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/), and the prediction of their target genes was performed using nine additional algorithms, including TargetScan, DIANAmT, miRanda, miRDB, RNAhybrid, PICTAR4, PICTAR5, PITA and RNA22.

To explore the functional annotation and pathway enrichment of those predicted genes, the Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) database analyses were conducted using a DAVID (the Database for Annotation, Visualization and Integrated Discovery) online analysis tool (Huang da et al. 2009) (http://david.abcc.ncifcrf.gov/tools.jsp), in which we focused on the GO biology process (BP) feature.

### Statistical analysis

The microarray data were analyzed by the algorithm of SAM (significance analysis of microarrays, www-stat.stanford.edu/~tibs/SAM/) (Olson 2006). The false discovery rate (FDR) was set to < 0.05 and the minimum fold change (FC) was set to > 2.0 or < 0.5. Hierarchical clustering was carried out using the MeV 4.9 software (Multi Experiment Viewer, http://www.tm4.org/mev.htm) to generate both miRNA and sample
trees based on Pearson correlation. For the RT-qPCR data, statistical analysis was performed by SPSS version 20.0 (SPSS, USA). Data were compared by Mann-Whitney U test, Kruskal-Wallis test and Spearman’s rank order correlations as appropriate. In bioinformatics analysis, the Fisher’s exact test and $\chi^2$ test were used to select the significant GO category or KEGG pathway, and the FDR was calculated to correct the $P$ value. A $P$-value < 0.05 was considered to be statistically significant.

Results

Patients characteristics

Demographic and clinical characteristics of the screening and validation cohorts at the time of renal biopsy are provided in Table 1 and Table 2 respectively. There were no significant differences in age and MAP among different groups in both cohorts. In the screening cohort, the levels of UPE in IgAN grade I-II and III subgroups were lower than that in MCD group (all $P < 0.01$) and higher than that in healthy control (HC) group (all $P < 0.01$); the levels of Scr in IgAN grade IV-V subgroup were higher than that in both MN and HC group (all $P < 0.05$), whereas the levels of eGFR showed an opposite trend. In the validation cohort, the levels of UPE in IgAN group were lower than that in MN and MCD group (all $P < 0.01$), but higher than that in HC group ($P < 0.001$); the levels of Scr were higher than that in all control groups (all $P < 0.01$), whereas the levels of eGFR showed an opposite trend. The histopathological parameters are shown in Table 3.

The yield of RNA from urinary sediments

RNA yield from urinary sediments (ng of RNA isolated from per ml of urine) was determined and showed no significant differences among patients with IgAN, MN, MCD and healthy subjects. The overall median was 22.73 ng/ml (interquartile range [IQR] = 10.75 - 40.35). A260/280 was also recorded and showed no significant differences among different groups in the present study. The overall mean of A260/280 was 1.95
Differentially expressed miRNAs in the screening phase

Global miRNA profiling from microarray analysis

To identify miRNAs differentially expressed in IgAN, miRNA microarrays were used to analyze their global expression profile of the four groups (IgAN, MN, MCD and HC). The 32 urine samples of the screening cohort were profiled on Affymetrix GeneChip miRNA 4.0 Arrays.

Among 2,578 mature human miRNAs represented on the microarray, 780 (30.3%) miRNAs were identified as expressed in at least one urine sample. Unsupervised hierarchical clustering analysis demonstrated that miRNA profiling clearly differentiated IgAN samples from healthy controls; there were, however, one MN sample and two MCD samples mixed with IgAN, indicating that the differences between IgAN patients and disease controls were not as clear (Figure 1).

Differentially expressed miRNAs in IgAN

The microarray data were analyzed by SAM; the results identified various differentially expressed miRNAs that presented a FC > 2 or < 0.5 and P value < 0.05 in urinary sediments of IgAN samples. Among them, there were 117 miRNAs differentially expressed between IgAN and HC (Table S1); 78 miRNAs differentially expressed between IgAN and MN (Table S2); and 11 miRNAs differentially expressed between IgAN and MCD (Table S3). There was not a single miRNA, however, that showed significantly different expression across all four groups.

Differentially expressed miRNAs in IgAN subgroups

In the screening phase, we grouped IgAN grade I–II as the early pathological change group; grade III as the mild pathological change group; and grade IV–V as the severe group according to Lee’s grading system. Then we compared the different subgroups of IgAN (grade I-II, III and IV-V) with both healthy and
disease controls. The differentially expressed miRNAs are shown in the form of volcano plot (Figure S1) and Venn diagram (Figure 2). All these miRNAs presented a FC > 2 or < 0.5 and P value < 0.05.

In the IgAN grade I–II subgroup, two miRNAs (hsa-miR-223-3p, hsa-miR-629-5p) were in high levels and two (hsa-miR-3613-3p, hsa-miR-4668-5p) were in low levels compared to all of the control groups (Figure 2A). In the IgAN grade III subgroup, three miRNAs (hsa-miR-150-5p, hsa-miR-572 and hsa-miR-371b-5p) were in high levels and three (hsa-miR-3613-3p, hsa-miR-4668-5p and hsa-miR-6750-5p) were in low levels compared to all control groups (Figure 2B). IgAN grade I-II and III subgroups shared dysregulation of only two miRNAs (miR-3613-3p and miR-4668-5p). Interestingly, there were no overlaps in changes to miRNAs for IgAN grade IV-V subgroup as shown in the Venn diagram (Figure 2C). It turned out that miRNAs were in different levels only in specific IgAN subgroups.

Validation of differentially expressed miRNAs using RT-qPCR

To check the accuracy of the microarray-based miRNA quantification, the eight above-mentioned miRNAs (miR-223-3p, miR-629-5p, miR-150-5p, miR-572, miR-371b-5p, miR-3613-3p, miR-4668-5p and miR-6750-5p) were re-examined using RT-qPCR in the 32 samples of the screening cohort. Then we analyzed correlations between log$_{2}$-transformed microarray signal and RT-qPCR Ct values.

As shown in Table 4, seven of the eight miRNAs (miR-223-3p, miR-629-5p, miR-150-5p, miR-572, miR-371b-5p, miR-3613-3p and miR-4668-5p) demonstrated significant correlations (|r| > 0.7, P < 0.01) between the two sets of measurements, indicating that the microarray data was relatively reliable.

Analysis of candidate miRNAs in the validation phase

Validation of candidate miRNAs using RT-qPCR

For confirmation purposes, the two miRNAs (miR-3613-3p and miR-4668-5p) that were differentially expressed in both IgAN grade I-II and III subgroups in the screening phase were selected as candidates and analyzed in the validation cohort, which included 102 patients with IgAN, 41 patients with MN, 27 patients...
with MCD and 34 healthy controls.

RT-qPCR results showed that the levels of miR-3613-3p were significantly lower in IgAN as compared with that in HC, MN and MCD, respectively [0.27 (0.19 - 0.38) vs 1.10 (0.9 - 1.26), 0.58 (0.32 - 1.00) and 0.61 (0.39 - 0.77), respectively, all \( P < 0.01 \)] (Figure 3A); the levels of miR-4668-5p were significantly lower in IgAN than that in HC [0.54 (0.38 - 0.60) vs 1.11 (0.73 - 1.22), \( P = 0.001 \)]; there were no significant differences for miR-4668-5p, however, between IgAN and the disease controls (Figure 3B).

**Correlations between candidate miRNAs and clinical parameters**

Correlations between urinary levels of candidate miRNAs and clinical parameters, such as UPE, Scr, eGFR and Lee’s grades, were further analyzed within the IgAN group (Table 5). Urinary levels of miR-3613-3p were positively correlated with both UPE (\( r = 0.50, P = 0.034 \)) and Lee’s grades (\( r = 0.57, P = 0.014 \)), while negatively correlated with eGFR (\( r = -0.48, P = 0.043 \)). Similarly, significant correlations were found between urinary levels of miR-4668-5p with eGFR (\( r = -0.50, P = 0.034 \)) and Lee’s grades (\( r = 0.57, P = 0.013 \)).

In addition, relationships between expressions of candidate miRNAs and four components of Oxford classification are shown in Figure 4. For segmental glomerulosclerosis, patients scored as S0 had significantly lower levels of urinary miR-3613-3p and miR-4668-5p than those scored as S1 [0.23 (0.12 - 0.33) vs 0.56 (0.29 - 2.50), 0.23 (0.18 - 0.25) vs 0.53 (0.35 - 1.90), respectively, all \( P < 0.05 \)].

**Bioinformatics analysis of candidate miRNAs**

**Predicted target genes of candidate miRNAs**

Only 3 out of 10 algorithms of miRWalk (DIANAmT, miRDB and Targetscan) can query the predicted target genes of miR-3613-3p and miR-4668-5p. For miR-3613-3p, there were 5138, 2292 and 1249 target genes predicted by DIANAmT, miRDB and Targetscan, respectively. For miR-4668-5p, there were 1766, 1169 and 552 target genes predicted by DIANAmT, miRDB and Targetscan, respectively. To reduce
redundancy, only genes predicted by all three algorithms were selected for further analysis; that is, 593 predicted targets genes for miR-3613-3p and 175 predicted targets genes for miR-4668-5p (data not shown).

**Functions and pathway analysis of miRNAs targets**

To explore in-depth biological information, the GO and KEGG database analyses were conducted using a DAVID online analysis tool. All of the significant GO Biological Processes for miR-3613-3p and miR-4668-5p are listed in Table S4 and Table S5 respectively; the top 20 GO Biological Processes according to $P$ values and all significant KEGG pathways for miR-3613-3p and miR-4668-5p are shown in Figure 5 and Figure 6 respectively.

There were 254 and 49 significant GO terms for miR-3613-3p and miR-4668-5p respectively ($P < 0.05$). The most significantly enriched GO terms for miR-3613-3p were the regulation of transcription (GO: 0045449, GO: 0006350) and macromolecule metabolic process (GO: 0010604, GO: 0010557) as shown in Figure 5A; it also had significant enrichment in B cell differentiation (GO: 0030183, $P = 0.006$) and activation (GO: 0042113, $P = 0.016$) as listed in Table S4. Similarly, the most significantly enriched GO terms for miR-4668-5p (as shown in Figure 6A) also included transcription (GO: 0006350, GO: 0045449) and macromolecule metabolic process (GO: 0051252, GO: 0010558), as well as nuclear transport (GO: 0006607, GO: 0051169).

In addition, as shown in Figure 6, there were 18 and 2 significant KEGG pathways for miR-3613-3p and miR-4668-5p respectively ($P < 0.05$); both included Wnt signaling pathway (hsa04310, $P = 0.012$ and $P = 0.013$ respectively).

**Discussion**

Genome-wide analyses of miRNA expressions in peripheral blood mononuclear cells (PBMCs) and kidney biopsy tissues have identified a number of miRNAs differentially expressed in patients with IgAN compared to healthy controls (Serino et al. 2012; Tan et al. 2013). In the present study, our microarray data also showed that there were a number of miRNAs that were up-regulated in urinary sediments of IgAN...
patients when compared with healthy subjects. However, the differentially expressed miRNAs identified in the three studies were not completely consistent with each other, which may be due to the use of different tissues and/or the possible effect of the different races of the subjects. It is therefore important to investigate miRNA profiles from different races in a larger study.

Wang et al. (Wang et al. 2011; Wang et al. 2012) quantified urinary levels of several miRNAs in 43 patients with IgAN and 13 healthy volunteers and found that the levels of miR-146a, miR-155 and miR-93 of IgAN were significantly higher than those of healthy controls, which are consistent with our microarray results. But these studies lacked disease controls to prove whether the differentially expressed miRNAs are disease-specific for IgAN. In theory, any aberrant miRNA expression observed in IgAN patients could be either disease-specific or present in all patients with chronic kidney disease (Szeto & Li 2014). Thus, in the present study, we recruited patients with MN or MCD as other glomerulopathy controls and explored the whole urinary miRNA profile in IgAN patients.

Analyses of our microarray data demonstrated that although the urinary miRNA profilings of IgAN samples were clearly differentiated from healthy controls, they were mixed to a certain degree with disease controls; that is, no miRNA was found to be disease-specific for IgAN at the screening phase of this study. Thus, we performed subgroup analyses according to Lee’s grading system, the results showed that eight miRNAs were differentially expressed either in the IgAN grade I-II subgroup or in the IgAN grade III subgroup compared to all control groups, but no miRNA was specific in the IgAN grade IV-V subgroup. This result may be explained by considerable histologic variability of IgAN, which ranges from no detectable histologic lesion to diffuse proliferative glomerulonephritis, and these cumulative changes may eventually results in glomerulosclerosis and tubulointerstitial fibrosis that are common in patients with chronic kidney disease (Haas & Reich 2012; Loeffler & Wolf 2014).

When studying the validation cohort, we verified that miR-3613-3p was in significantly low levels in urinary sediments of IgAN patients compared to healthy controls and MN or MCD patients, indicating it may have potential diagnostic value for IgAN. But it is necessary to note that the pathological grades of IgAN
patients enrolled in this study were predominantly grade II (16.7%), III (51.0%), and IV (23.5%) according to Lee’s grading system, while grades I (3.9%) and V (4.9%) were rare. This phenomenon is also consistent with previous studies (Bartosik et al. 2001; Lee et al. 2005). In the present study, we also observed that the expression levels of miR-3613-3p and miR-4668-5p were significantly correlated with eGFR, Lee’s grades and glomerulosclerosis, indicating that there may be a possible correlation between the levels of the two miRNAs and the severity of IgAN.

New evidences are emerging that IgAN is an immune-mediated disease with galactose-deficient IgA1, which can elicit an autoantibody response and formation of immune complexes that are deposited in the mesangium (Kiryluk & Novak 2014; Pillai et al. 2014). Although miR-3613-3p and miR-4668-5p were reported with unknown biological functions, bioinformatics analysis may shed light on the roles of these miRNAs by predicting miRNA-regulated genes. According to the GO analysis, the predicted functions of both miR-3613-3p and miR-4668-5p were significantly enriched in regulation of transcription and macromolecule metabolic process, which is consistent with the study of Tan et al (Tan et al. 2013). Moreover, the gene functions predicted by miR-3613-3p was also significantly enriched in B cell differentiation and activation, which may be related to the mechanism of IgAN.

According to the KEGG analysis, the predicted pathways of both miR-3613-3p and miR-4668-5p were significantly enriched in Wnt signaling pathway. It was reported previously that Wnt proteins are mitogenic for pro-B cells (Reya et al. 2000). Moreover, a recent study has shown that the Wnt pathway was hyper-activated in PBMCs of IgAN patients, and the proliferation rate of PBMCs isolated from IgAN patients was significantly enhanced (Cox et al. 2010). Therefore, we make a hypothesis that the decreased expression of miR-3613-3p might regulate the activation of B cells through Wnt pathway, and participate in the pathogenesis of IgAN, providing a direction for further functional studies.

There are a few limitations of our study. First, we detected urinary levels of candidate miRNAs without determining their cellular source. MiRNAs in urinary sediments presumably reflect cellular miRNA content, including podocytes, inflammatory cells, deciduous renal tubular epithelial cells and cells from urinary tract,
but not including exosomes because of the relatively low g values during centrifugation. Future studies would be necessary to investigate cellular sources of candidate miRNAs. Secondly, as the bioinformatics analysis is notoriously inaccurate, the underlying mechanism of the changes and correlations observed in this study needs further investigation.

In summary, the expression profile of miRNAs was significantly altered in urinary sediments from IgAN patients, and the microarray data provided a valuable repertoire to discover non-invasive biomarkers for IgAN. Further studies with larger numbers of patients and controls, especially in different races, are urgently needed to validate the expression profiles. Urinary expression of \textit{miR-3613-3p} was down-regulated in patients with IgAN, and the levels of both \textit{miR-3613-3p} and \textit{miR-4668-5p} were correlated with disease severity. Further studies are needed to explore the roles of \textit{miR-3613-3p} and \textit{miR-4668-5p} in the pathogenesis and progression of IgA nephropathy.

References

Bartosik LP, Lajoie G, Sugar L, and Cattran DC. 2001. Predicting progression in IgA nephropathy. \textit{Am J Kidney Dis} 38:728-735.

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL et al. . 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. \textit{Clin Chem} 55:611-622.

Chandrasekaran K, Karolina DS, Sepramaniam S, Armugam A, Wintour EM, Bertram JF, and Jeyaseelan K. 2012. Role of microRNAs in kidney homeostasis and disease. \textit{Kidney Int} 81:617-627.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X et al. . 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. \textit{Cell Res} 18:997-1006.

Cox SN, Sallustio F, Serino G, Pontrelli P, Verrienti R, Pesce F, Torres DD, Ancona N, Stifanelli P, Zaza G et al. . 2010. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. \textit{Kidney Int} 78:396-407.

Dweep H, Sticht C, Pandey P, and Gretz N. 2011. miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. \textit{J Biomed Inform} 44:839-847.

Esteller M. 2011. Non-coding RNAs in human disease. \textit{Nat Rev Genet} 12:861-874.

Haas M, and Reich HN. 2012. Morphologic markers of progressive immunoglobulin A nephropathy. \textit{Adv Chronic Kidney Dis} 19:107-113.

Huang da W, Sherman BT, and Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. \textit{Nat Protoc} 4:44-57.

Kiryluk K, and Novak J. 2014. The genetics and immunobiology of IgA nephropathy. \textit{J Clin Invest} 124:2325-2332.

Kozomara A, and Griffiths-Jones S. 2011. miRBase: integrating microRNA annotation and deep-sequencing data. \textit{Nucleic Acids Res} 39:D152-157.
Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, Park SY, Han JS, Kim S, and Lee JS. 2005. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. *Nephrol Dial Transplant* 20:342-348.

Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, and Katz Al. 1982. IgA nephropathy: morphologic predictors of progressive renal disease. *Hum Pathol* 13:314-322.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al. 2009. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150:604-612.

Livak KJ, and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.

Loeffler I, and Wolf G. 2014. Transforming growth factor-beta and the progression of renal disease. *Nephrol Dial Transplant* 29 Suppl 1:i37-i45.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, and Vandesompele J. 2009. A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biol* 10:R64.

Olson NE. 2006. The microarray data analysis process: from raw data to biological significance. *NeuroRx* 3:373-383.

Pillai U, Balabhadraputani K, and Bhat Z. 2014. Immunoglobulin A nephropathy: a review of current literature on emerging pathophysiology. *Am J Med Sci* 347:249-253.

Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, Nusse R, and Grosschedl R. 2000. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. *Immunity* 13:15-24.

Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC et al. 2009. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney Int* 76:546-556.

Schena FP. 1990. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. *Am J Med* 89:209-215.

Serino G, Sallustio F, Cox SN, Pesce F, and Schena FP. 2012. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. *J Am Soc Nephrol* 23:814-824.

Szeto CC, and Li PK. 2014. MicroRNAs in IgA nephropathy. *Nat Rev Nephrol* 10:249-256.

Tan K, Chen J, Li W, Chen Y, Sui W, Zhang Y, and Dai Y. 2013. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. *Genome* 56:161-169.

Wang G, Kwan BC, Lai FM, Chow KM, Kam-Tao Li P, and Szeto CC. 2010. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. *Dis Markers* 28:79-86.

Wang G, Kwan BC, Lai FM, Chow KM, Li PK, and Szeto CC. 2011. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. *Dis Markers* 30:171-179.

Wang G, Kwan BC, Lai FM, Chow KM, Li PK, and Szeto CC. 2012. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. *Am J Nephrol* 36:412-418.

Wang G, and Szeto CC. 2013. Methods of microRNA quantification in urinary sediment. *Methods Mol Biol* 1024:211-220.

Wyatt RJ, and Julian BA. 2013. IgA nephropathy. *N Engl J Med* 368:2402-2414.
Global urinary miRNA profiling in patients with IgAN and controls.

Unsupervised hierarchical clustering using log₂-transformed microarray signal values of the 780 expressed miRNAs is shown as a heat-map. Columns represent urine samples and rows miRNAs. Urine samples were from 18 patients with IgAN (red), 6 healthy subjects (orange), 4 patients with MN (dark blue) and 4 patients with MCD (light blue). Heat-map colours represent relative miRNA expression as indicated in the colour scale: yellow represents high expression; blue represents low expression; black represents median expression level equal to 1. HC, healthy control; IgAN, IgA nephropathy; I-II, III and IV-V, grade I-II, III and IV-V according to Lee’s grading system, respectively; MN, membranous nephropathy; MCD, minimal change disease.
Overlapping relationship of the differentially expressed miRNAs in IgAN subgroups.

Urinary levels of miRNAs in the subgroups of IgAN (IgAN grade I-II, III and IV-V subgroup according to Lee’s grading system) were compared with each control group (HC, MN and MCD) in the screening phase. All differentially expressed miRNAs presented a fold change > 2 and \( P \) value < 0.05. The miRNAs in the centre of Venn diagram were (A) \( \text{miR-223-3p, miR-629-5p, miR-3613-3p and miR-4668-5p} \); (B) \( \text{miR-150-5p, miR-572, miR-371b-5p, miR-3613-3p, miR-4668-5p and miR-6750-5p} \). IgAN, IgA nephropathy; HC, healthy control; MN, membranous nephropathy; MCD, minimal change disease.
Comparison of candidate miRNAs levels between IgAN and each control group.

Urinary levels of candidate miRNAs were analyzed by RT-qPCR in the validation cohort, which including 102 patients with IgAN, 41 patients with MN, 27 patients with MCD and 34 healthy controls. The whisker-box plots depict the relative expression level of \textit{miR-3613-3p} and \textit{miR-4668-5p}. The boxes indicate median and 25th and 75th percentiles; whisker caps indicate 5th and 95th percentiles. Statistically significant differences were determined by Mann-Whitney U test. Levels are represented as ratio to the median of healthy controls. NS, not significant (\( P > 0.05 \)); IgAN, IgA nephropathy; HC, healthy control; MN, membranous nephropathy; MCD, minimal change disease. (A) Urinary \textit{miR-3613-3p} levels was significantly lower in IgAN as compared with that in HC, MN and MCD, respectively [0.27 (0.19 - 0.38), \( n = 102 \) vs 1.10 (0.9 - 1.26), \( n = 34 \); 0.58 (0.32 - 1.00), \( n = 41 \) and 0.61 (0.39 - 0.77), \( n = 27 \); respectively, all \( P < 0.01 \)]. (B) Urinary \textit{miR-4668-5p} levels were significantly lower in IgAN than that in HC [0.54 (0.38 - 0.60), \( n = 102 \) vs 1.11 (0.73 - 1.22), \( n = 34 \); \( P = 0.001 \)]. Urinary \textit{miR-4668-5p} levels there were were not different between IgAN and MN and MCD [0.54 (0.38 - 0.60), \( n = 102 \) vs 0.56 (0.41 - 0.88), \( n = 41 \) and 0.65 (0.49 - 0.87), \( n = 27 \); respectively].
Relationships between candidate miRNAs levels and pathological parameters in patients with IgAN according to Oxford classification.

The whisker-box plots with medians and inter-quartile ranges depict the relative expression level of miR-3613-3p and miR-4668-5p. Data were analyzed by Mann-Whitney U test. IgAN, IgA nephropathy; HC, healthy control; MN, membranous nephropathy; MCD, minimal change disease. (A) Urinary miR-3613-3p levels of patients with S1 were higher than patients with S0 [0.56 (0.29 - 2.5), n = 69 vs 0.23 (0.12 - 0.33), n = 33; P = 0.019]. Urinary miR-3613-3p levels of patients with M1/M0, E1/E0 and T2/T1/T0 were not different between each other [0.28 (0.21 - 1.52), n = 43 vs 0.51 (0.31 - 1.3), n = 59; 0.55 (0.26 - 1.61), n = 13 vs 0.49 (0.26 - 1.22), n = 89; 2.58 (0.81 - 9.18), n = 9 vs 0.72 (0.5 - 1.3) vs 0.33 (0.23 - 0.51), n = 56]. (B) Urinary miR-4668-5p levels of patients with S1 were higher than patients with S0 [0.53 (0.35 - 1.9), n = 69 vs 0.23 (0.18 - 0.25), n = 33; P = 0.019]. Urinary miR-4668-5p levels of patients with M1/M0, E1/E0 and T2/T1/T0 were not different between each other [0.33 (0.26 - 1.55), n = 43 vs 0.41 (0.3 - 0.94), n = 59; 0.43 (0.32 - 1.55), n = 13 vs 0.4 (0.24 - 0.94), n = 89; 2.18 (0.73 - 3.13), n = 9 vs 0.43 (0.36 - 0.89) vs 0.35 (0.23 - 0.41), n = 56].
GO biology process and KEGG pathway enrichment analysis for predicted miRNA targets of \textit{miR-3613-3p}.

GO biology process and KEGG pathway enrichments were performed by mapping the predicted target genes using DAVID online analysis tool. $P < 0.05$ was used as a threshold to select significant GO terms and KEGG pathways. $-\lg(P \text{ value})$ is the negative log10 of the $P$ value. The top 20 GO biology processes according to $-\lg(P \text{ value})$ and a total of 18 KEGG pathways for \textit{miR-3613-3p} were annotated. GO, Gene Ontology; BP, biology process; KEGG, Kyoto Encyclopedia of Genes and Genomes.
A

-\lg(P\ value)

| GO category BP | -\lg(P value) |
|----------------|--------------|
| GO:0045449     | 10           |
| GO:0006350     | 10           |
| GO:0010604     | 10           |
| GO:0010557     | 10           |
| GO:0009891     | 10           |
| GO:0051252     | 10           |
| GO:0031328     | 10           |
| GO:0010628     | 10           |
| GO:0045541     | 10           |
| GO:00455935    | 10           |
| GO:0006555     | 10           |
| GO:0051179     | 10           |
| GO:0006357     | 10           |
| GO:00455893    | 10           |
| GO:0051254     | 10           |
| GO:0010629     | 10           |
| GO:0016481     | 10           |
| GO:0031327     | 10           |
| GO:0010605     | 10           |
| GO:0010558     | 10           |

GO:0045449 - regulation of transcription
GO:0006350 - transcription
GO:0010604 - positive regulation of macromolecule metabolic process
GO:0010557 - positive regulation of macromolecule biosynthetic process
GO:0006555 - negative regulation of macromolecule metabolic process
GO:0009891 - positive regulation of biosynthetic process
GO:0051179 - regulation of RNA metabolic process
GO:0051252 - regulation of RNA metabolic process
GO:0031328 - positive regulation of cellular biosynthetic process
GO:0010628 - positive regulation of gene expression
GO:0045541 - positive regulation of transcription
GO:00455935 - positive regulation of nucleoside, nucleoside, nucleotide and nucleic acid metabolic process
GO:0006355 - regulation of transcription, DNA-dependent
GO:0051173 - positive regulation of nitrogen compound metabolic process
GO:0006557 - regulation of transcription from RNA polymerase II promoter
GO:00455893 - positive regulation of transcription, DNA-dependent
GO:0051254 - positive regulation of RNA metabolic process
GO:0010629 - negative regulation of gene expression
GO:0016481 - negative regulation of transcription
GO:0031327 - negative regulation of cellular biosynthetic process
GO:0010605 - negative regulation of macromolecule metabolic process
GO:0010558 - negative regulation of macromolecule biosynthetic process

B

-\lg(P\ value)

| KEGG pathway | -\lg(P value) |
|--------------|--------------|
| hsa04520     | 5            |
| hsa04910     | 5            |
| hsa04120     | 5            |
| hsa05215     | 5            |
| hsa04330     | 5            |
| hsa04720     | 5            |
| hsa04111     | 5            |
| hsa04960     | 5            |
| hsa04310     | 5            |
| hsa05216     | 5            |
| hsa04915     | 5            |
| hsa04722     | 5            |
| hsa04360     | 5            |
| hsa03018     | 5            |
| hsa05130     | 5            |
| hsa05221     | 5            |
| hsa04320     | 5            |

hsa04520 - Adherens junction
hsa04910 - Insulin signaling pathway
hsa04120 - Ubiquitin-mediated proteolysis
hsa05215 - Prostate cancer
hsa04330 - Notch signaling pathway
hsa05200 - Pathways in cancer
hsa04720 - Long-term potentiation
hsa04111 - Oocyte meiosis
hsa04960 - Aldosterone-regulated sodium reabsorption
hsa04310 - Wnt signaling pathway
hsa05216 - Thyroid cancer
hsa04915 - Melanogenesis
hsa04722 - Wnt signaling pathway
hsa04360 - Axon guidance
hsa03018 - RNA degradation
hsa05130 - Pathogenic Escherichia coli infection
hsa05221 - Acute myeloid leukemia
hsa04320 - Dorsal-ventral axis formation
GO biology process and KEGG pathway enrichment analysis for predicted miRNA targets of *miR-4668-5p*.

GO biology process and KEGG pathway enrichments were performed by mapping the predicted target genes using DAVID online analysis tool. \( P < 0.05 \) was used as a threshold to select significant GO terms and KEGG pathways. \(-\lg(P \text{ value})\) is the negative log10 of the \( P \) value. The top 20 GO biology processes according to \(-\lg(P \text{ value})\) and a total of 2 KEGG pathways for *miR-4668-5p* were annotated. GO, Gene Ontology; BP, biology process; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Table 1 (on next page)

Demographic and clinical data of subjects in the screening cohort.

Continuous data are presented as mean±SEM; categorical data are presented as counts. IgAN, IgA nephropathy; MN, membranous nephropathy; MCD, minimal change disease; HC, healthy control; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR; estimated glomerular filtration rate.
Table 1. Demographic and clinical data of subjects in the screening cohort.

|                | IgAN I-II | IgAN III | IgAN IV-V | MN   | MCD  | HC   |
|----------------|-----------|----------|-----------|------|------|------|
| Cases          | 6         | 6        | 6         | 4    | 4    | 6    |
| Gender (M/F)   | 3/3       | 3/3      | 3/3       | 2/2  | 2/2  | 3/3  |
| Age (years)    | 27±5.3    | 32.3±9.3 | 36.3±10.5 | 25.8±3.1 | 33.3±8.5 | 31.2±8.4 |
| MAP (mmHg)     | 88.78±5.01| 90.89±2.93| 101±9.3   | 91.42±10.85 | 91.92±14.71 | 87.21±4.87 |
| UPE (g/day)    | 1.21±1.78 | 0.82±0.75 | 1.73±0.52 | 4.17±1.66 | 8.15±2.22 | 0.008±0.003 |
| Scr (µmol/L)   | 78.7±20.22| 87.3±35.56| 126.23±23.12| 61.63±19.50 | 82.58±25.63 | 59.14±10.25 |
| eGFR (ml/min/1.73m²) | 102.93±15.89 | 94.64±23.97 | 57.57±17.48 | 129.29±17.54 | 97.48±28.47 | 135.46±12.87 |
| Oxford classification | | | | | | |
| M0/M1          | 6/0       | 2/4      | 3/3       | —    | —    | —    |
| E0/E1          | 6/0       | 5/1      | 6/0       | —    | —    | —    |
| S0/S1          | 4/2       | 1/5      | 0/6       | —    | —    | —    |
| T0/T1/T2       | 6/0/0     | 3/2/1    | 0/1/5     | —    | —    | —    |

Continuous data are presented as mean±SEM; categorical data are presented as counts. IgAN, IgA nephropathy; MN, membranous nephropathy; MCD, minimal change disease; HC, healthy control; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR, estimated glomerular filtration rate.
Table 2 (on next page)

Demographic and clinical data of subjects in the validation cohort.

Continuous data are presented as mean±SEM; categorical data are presented as counts and/or proportions. IgAN, IgA nephropathy; MN, membranous nephropathy; MCD, minimal change disease; HC, healthy control; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR, estimated glomerular filtration rate.
Table 2. Demographic and clinical data of subjects in the validation cohort.

|                | IgAN | MN  | MCD | HC  | IgAN vs MN | IgAN vs MCD | IgAN vs HC |
|----------------|------|-----|-----|-----|------------|-------------|------------|
| Cases          | 102  | 41  | 27  | 34  | —          | —           | —          |
| Gender (M/F)   | 57(55.77%) | 24(58.54%) | 69(22.22%) | 17(50%) | 0.857      | 0.008       | 0.489      |
| Age (years)    | 35.87±11.82 | 35.8±9.3 | 31.6±10.9 | 33.1±7.9 | 0.935      | 0.963       | 0.659      |
| MAP (mmHg)     | 95.53±12.16 | 94.17±9.72 | 88.69±10.89 | 86.59±7.35 | 0.763      | 0.149       | 0.061      |
| UPE (g/day)    | 1.57±1.28  | 4.61±2.61 | 7.01±2.86  | 0.015±0.013 | <0.001     | <0.001      | <0.001     |
| Scr (µmol/L)   | 105.89±51.68 | 69.47±17.05 | 78.08±22.12 | 61.0±11.89 | <0.001     | 0.003       | <0.001     |
| eGFR (ml/min/1.73m²) | 80.76±29.65 | 119.62±18.77 | 100.87±24.56 | 126.54±10.85 | <0.001     | 0.038       | <0.001     |

Continuous data are presented as mean±SEM; categorical data are presented as counts and/or proportions. IgAN, IgA nephropathy; MN, membranous nephropathy; MCD, minimal change disease; HC, healthy control; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR; estimated glomerular filtration rate.
Table 3 (on next page)

Histopathological characteristics of patients with IgAN.

IgAN, IgA nephropathy. According to the Oxford classification, four variables were evaluated; that is, mesangial proliferation (M), segmental glomerulosclerosis (S), endocapillary hypercellularity (E) and tubular atrophy/interstitial fibrosis (T).
Table 3. Histopathological characteristics of patients with IgAN.

| Oxford classification | Lee's grade |   |   |   | Total |
|-----------------------|-------------|---|---|---|-------|
|                       | I           | II | III | IV | V     |
| M0/M1                 | 4/0         | 17/0 | 31/21 | 6/18 | 1/4 | 59/43 |
| E0/E1                 | 4/0         | 15/2 | 43/9 | 22/2 | 5/0 | 89/13 |
| S0/S1                 | 4/0         | 14/3 | 12/40 | 3/21 | 0/5 | 33/69 |
| T0/T1/T2              | 4/0/0       | 14/3/0 | 38/14/0 | 0/20/4 | 0/0/5 | 56/37/9 |
| Total                 | 4           | 17   | 52  | 24  | 5   | 102   |

IgAN, IgA nephropathy. According to the Oxford classification, four variables were evaluated; that is, mesangial proliferation (M), segmental glomerulosclerosis (S), endocapillary hypercellularity (E) and tubular atrophy/interstitial fibrosis (T).
Table 4 (on next page)

Correlations between miRNA quantification by microarray and RT-qPCR.

RT-qPCR, real-time quantitative polymerase chain reaction; r, Spearman correlation coefficient; 95% CI, 95% confidence interval.
| miRNA     | r    | 95% CI      | P value |
|-----------|------|-------------|---------|
| miR-223-3p | -0.86| -0.93 ~ -0.72 | <0.001 |
| miR-629-5p | -0.74| -0.87 ~ -0.52 | <0.001 |
| miR-150-5p | -0.93| -0.97 ~ -0.8  | <0.001 |
| miR-572   | -0.82| -0.91 ~ -0.68 | <0.001 |
| miR-371b-5p| -0.77| -0.88 ~ -0.58 | <0.001 |
| miR-3613-3p| -0.84| -0.94 ~ -0.66 | <0.001 |
| miR-4668-5p| -0.72| -0.88 ~ -0.46 | <0.001 |
| miR-6750-5p| -0.37| -0.67 ~ -0.01 | 0.04   |

RT-qPCR, real-time quantitative polymerase chain reaction; r, Spearman correlation coefficient; 95% CI, 95% confidence interval.
Table 5 (on next page)

Correlations between candidate miRNAs and clinical parameters in patients with IgA nephropathy.

$r$, Spearman correlation coefficient; 95% CI, 95% confidence interval; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR, estimated glomerular filtration rate.
Table 5. Correlations between candidate miRNAs and clinical parameters in patients with IgA nephropathy.

|       | miR-3613-3p |          |       | miR-4668-5p |          |       |
|-------|-------------|----------|-------|-------------|----------|-------|
|       | r           | 95% CI   | P value | r           | 95% CI   | P value |
| Age   | 0.12        | -0.37 ~ 0.54 | 0.631 | 0.26        | -0.28 ~ -0.67 | 0.29   |
| MAP   | 0.42        | -0.06 ~ 0.72 | 0.084 | 0.34        | -0.19 ~ -0.73 | 0.173  |
| UPE   | 0.501       | 0.03 ~ 0.83  | 0.034 | 0.44        | -0.05 ~ -0.76 | 0.066  |
| Scr   | 0.451       | -0.06 ~ 0.79  | 0.06  | 0.42        | -0.06 ~ -0.73 | 0.083  |
| eGFR  | -0.48       | -0.84 ~ 0.02  | 0.043 | -0.5        | -0.84 ~ -0.08 | 0.034  |
| Lee's grades | 0.57        | 0.07 ~ 0.84  | 0.014 | 0.57        | 0.04 ~ 0.85  | 0.013  |

r, Spearman correlation coefficient; 95% CI, 95% confidence interval; MAP, mean aortic pressure; UPE, 24-hour urinary protein excretion; Scr, serum creatinine; eGFR, estimated glomerular filtration rate.